Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
My first two molecular cancer markers for 1st April are in: CEA (colorectal cancer), down to 5.0 (just ‘good’), and CA19-9 (for pancreatic and colorectal cancer) at 79 (still ‘bad’ but a continuing improvement). As I had that CT scan to check out for any sign of cancerous growth (and came back as no indication that there was any), I am just testing these really for interest – I do not now think they are really showing cancerousness.
Meanwhile I am awaiting the more important CxBladder result.
Although individual immune checkpoint inhibitors have shown promise as cancer immunotherapies, recent data suggest that greater success will be ...
... an attempt to induce immune responses in patients with cancer. However, DC vaccines have so far shown limited efficacy in tumour immunotherapy, ...
Immunotherapies work in such a way that they fight diseases by using components of a patient's ...
Now, a small clinical study has found support for a newcomer on the cancer immunotherapy front. Injected with a vaccine designed to match specific ...
The underlying basis of cancer immunotherapy is to activate a patient's own T cells so that they can kill their tumors. Reports of amazing recoveries ...
The microbiome has also been shown to play a role in cancer. ... cancers like colon cancer, or why immunotherapy works better in some microbiomes ...
The company will present its results on a new immunotherapy targeting the Mucin1 (MUC1) protein in non-small cell lung cancer administered in ...
Low doses of the anti-cancer drug imatinib can spur the bone marrow to ... that imatinib can push the immune system to combat a variety of bacteria, ...
Now there's a new kind of cancer treatment on the horizon: immunotherapies. These treatments try to stimulate the immune system, often through ...
Immunotherapy is the fruition of a century-old idea: that a person's own immune system can be stimulated to fight cancer. Now breakthroughs are ...
There are over 100 different types of HPV; however, most types of HPV do not cause cancer. Typically our body's immune system gets rid of the virus ...
“It develops a memory in the immune system, so it can fight this at other ... This is a nationwide study with the Huntsman Cancer Institute playing one of ...
Bay Area cancer vaccine maker Bullet Biotechnology is developing a therapy for B cell lymphomas, hacking a patient's own immune system to treat ...
These are then injected back into the patients' body in order to fight cancer ... response from the immune system thus treating lot of cancer ailments.
Opinion: Upgrading Cancer Prevention
We know that a good number of cancers can be forestalled by avoiding tobacco, eating well, controlling weight, and limiting alcohol consumption. But it’s time now to move past these general admonishments and apply the powerful technologies and knowledge at our disposal to systematically develop more experimentally validated interventions to prevent other environmentally fueled cancers. Doing so is as much an economic necessity as it is a humanitarian imperative
A partnership between the Pancreatic Cancer Action Network and Perthera, a self-described “concierge” for molecular diagnostic testing, is giving ...
the metastatic pancreatic cancer patients who are ...
The GEMOXEL (gemcitabine, oxaliplatin, capecitabine) regimen may be safe and more efficient than standard therapy with gemcitabine alone in the ...
1. Omeprazole Inhibits Pancreatic Cancer Cell Invasion Through a Non-genomic Aryl. Hydrocarbon Receptor Pathway. Un-Ho Jin. †. , Sang-Bae Kim.
A groundbreaking new meta-analysis published in PLoS titled,"Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis", calls into question the value of using BRCA1/2 gene status to determine breast cancer survival prognosis, as is common practice today
This Explanation of Cancer Will Blow You Away!
OBJECTIVE: Spain is a country where bladder cancer incidence and mortality rates are some of the highest in the world. The aim of this study is to ...
He thinks the technique could also be used to treat lung cancer, bladder cancer, and colorectal cancer. "It opens the door to personalized ...
Costs and Effectiveness of Genomic Testing in the Management of Colorectal Cancer
Numerous genomic tests are available for use in colorectal cancer, with a widely variable evidence base for their effectiveness and cost-effectiveness. In this review, we highlight many of these tests, with a focus on their proposed role, the evidence base to support that role, and the associated costs and risks.
Numerous genomic tests are available for use in colorectal cancer, with a widely variable evidence base for their effectiveness and cost-effectiveness. In this review, we highlight many of these tests, with a focus on their proposed role, the evidence base to support that role, and the associated costs and risks.
Commentaries
Genomic Testing in Colorectal Cancer: How Much Is Enough?
The identification and characterization of gene signatures, driver events, and pharmacogenomics in molecularly homogeneous subsets of patients is likely to advance effective drug development strategies in colorectal cancer.
The identification and characterization of gene signatures, driver events, and pharmacogenomics in molecularly homogeneous subsets of patients is likely to advance effective drug development strategies in colorectal cancer.
Cost-Effectiveness of Genomic Testing for Colorectal Cancer: Are We There Yet?
Although genomic testing can improve the cost-effectiveness of a treatment, assessing the cost-effectiveness of genomic testing outside the context of its impact on treatment is not practical.
Although genomic testing can improve the cost-effectiveness of a treatment, assessing the cost-effectiveness of genomic testing outside the context of its impact on treatment is not practical.
Science Daily Cancer News
The micro RNA miR-22 has long been known for its ability to suppress cancer. However, questions remain about how it achieves this feat. For example, which molecules are regulating miR-22, and which are miR22 targets? Researchers have unraveled some of these relationships, identifying several interactions that directly impact liver and colon cancer.
Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial.
A vital self-destruct switch in cells can be hijacked, making some pancreatic and non small cell lung cancers more aggressive, according to research. Researchers found that mutations in the KRAS gene interferes with protective self-destruct switches, known as TRAIL receptors, which usually help to kill potentially cancerous cells.
Capitalizing on a rare opportunity to thoroughly analyze a tumor from a lung cancer patient who had developed resistance to targeted drug treatment, scientists identified a biological escape hatch that explains the resistance, and developed a strategy in mice for shutting it down.
22 genetic variations that are associated with an increased risk of developing prostate cancer have been identified by an international team of researchers. Prostate cancer affects one out of every 6 men during their lifetime and is the second most common cause of cancer-related death for men in the United States, resulting in an estimated 27,500 deaths in 2015.
In new research, investigators describe compulsive evolution and dramatic genetic diversity in cells belonging to one of the most treatment-resistant and lethal forms of blood cancer: acute myeloid leukemia (AML). The authors suggest the research may point to new paradigms in both the diagnosis and treatment of aggressive cancers, like AML.
An existing chemotherapy drug used to treat leukemia could prevent and control the growth of colorectal tumors, scientists have discovered.
Exercise and physical activity should be considered as therapeutic options for lung cancer as they have been shown to reduce symptoms, increase exercise tolerance, improve quality of life, and potentially reduce length of hospital stay and complications following surgery for lung cancer.
People over 60 are at higher risk of being diagnosed with lung or bowel cancer as an emergency in hospital than younger people, according to a report. The researchers also found that women and less affluent people are at higher risk of an emergency lung cancer diagnosis, while being unmarried, divorced or widowed was associated with having bowel cancer diagnosed as an emergency.
Key mechanism identified in pediatric bone cancers that allows proliferation of tumor-forming stem cells
A particular molecular pathway permits stem cells in pediatric bone cancers to grow rapidly and aggressively, according to researchers. In the study, the investigators used human and mouse osteosarcomas to pinpoint the molecular mechanisms that inhibit the tumor-suppressive Hippo pathway. The researchers concluded that Sox2 represses the functioning of the Hippo pathway, which, in turn, leads to an increase of the potent growth stimulator Yes Associated Protein, known as YAP, permitting cancer cell proliferation.
Delving into the world of the extremely small, researchers are exploring how biodegradable nanoparticles can precisely deliver anticancer drugs to attack neuroblastoma, an often-deadly children's cancer.
Tambahkan Komentar